Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19)

Interim guidance
20 March 2020

Background

This document provides interim guidance on the management of the blood supply in response to the pandemic outbreak of coronavirus disease (COVID-19). It is intended for blood services, national health authorities, and others responsible for the provision of blood and blood components and integration of the blood system within the public health system. WHO will continue to update this guidance as new information becomes available.

This document is adapted from the WHO Guidance for National Blood Services on Protecting the Blood Supply During Infectious Disease Outbreaks and risk assessment publications on COVID-19 from regional networks/institutions.

General considerations

The COVID-19 virus outbreak is primarily transmitted by the respiratory route and theoretically by transfusions. The epidemic has the potential to reduce the supply of blood and blood components and adversely affect blood system activities. Blood services should therefore take steps to assess, plan, and respond appropriately and proportionately.

The risk of transmission of COVID-19 through transfusion of blood and components is now only theoretical and likely minimal. But experience with outbreaks of other coronaviruses suggests that there will be significant impact on blood supplies through reduced blood donation.

Effective and accurate data-driven risk assessment is necessary to determine the most appropriate and proportionate action, taking into consideration: a) the extent of COVID-19 spread in the country or geographical area; b) level of community circulation (limited and contained vs widespread and sustained); c) local epidemiology; d) risk of transfusion transmission in context of overall burden of disease; e) quality of health care system; f) public health response; blood supply sufficiency; g) operational impacts; and h) cost effectiveness of blood safety interventions in reducing disease morbidity in relation to the overall situation in the country.

Blood services must be prepared to move quickly in response to changes, during which blood sufficiency is most likely to be affected. A national rather than sub-national or local approach should be adopted for coherence and coordination and to ensure public confidence in blood safety and supply. Blood services should be included in the national outbreak response, through experts linked to the national emergency response team. Blood services should activate their emergency response plans. Networks of cooperating blood services across regions can help maintain the availability of blood and blood components.

1. Mitigating the potential risk of transmission through the transfusion of blood and blood components

Respiratory viruses have never been reported to be transmitted through blood or blood components; therefore, any potential risk of transmission by transfusion of blood collected from asymptomatic individuals is theoretical. Any actions taken to mitigate risk are therefore precautionary. Options include donor education, self-deferral or deferral of at-risk donors, quarantine of blood components, retrieval of in-date products based on a report of post-donation illness in the donor, screening of donations using laboratory tests, and pathogen reduction:

a. Potential donors should be educated about the need to self-defer based on risk factors for COVID-19 or feeling unwell. Current donor screening measures excluding symptomatic individuals who are unwell or with signs and symptoms of fever and respiratory disease (such as cough or breathlessness) must be strictly complied with. Persons who donate should inform the blood centre immediately if they develop a respiratory illness within 28 days of donation.

b. Persons who have fully recovered from confirmed COVID-19, those with possible direct exposure to COVID-19 from a confirmed case, and those who have travelled from areas with ongoing community transmission should refrain from blood donation for at least 28 days. This may take the form of self-deferral or mandatory deferral. In the event of widespread transmission, donor restrictions based on definitions of exposure risk and duration of deferral may need to be reduced to fit the local situations so as not to affect availability of blood for critical transfusion therapy.

c. Quarantine of components with delayed release based on absence of a reported subsequent illness in the donor is an option in the event of widespread and sustained transmission. But this is difficult to implement and disrupts existing processes and workflows, leading to greater potential for errors. Release of blood into available inventory is delayed, and quarantine of platelets is particularly problematic given their short shelf-life.
d. A system must be in place for donors to report post-donation illness consistent with COVID-19 or contact with a case that is confirmed post-donation. Blood and components collected within 14 to 28 days of disease onset in the donor or after contact exposure may be recalled as a precautionary measure. Although risk of transfusion transmission is theoretical, notification of the clinician of confirmed infection in the donor may also be considered if the blood or components have been transfused.

e. Testing of the blood supply is premature in the absence of cases of transfusion transmission or demonstrated infectivity of the COVID-19 virus in blood collected from asymptomatic persons.

f. Pathogen reduction technologies (PRTs) have been demonstrated to be effective against SARS-CoV and MERS-CoV in plasma and platelets. However, PRT requires significant logistical and financial investment. PRT for whole blood is less widely available and studies of inactivation of coronaviruses in whole blood are lacking. Introduction of PRT for the COVID-19 virus would not be cost effective or proportionate and is not recommended.

g. Current manufacturing processes for plasma derivatives can inactivate and remove viruses related to the COVID-19 virus. As an enveloped virus, the COVID-19 virus is susceptible to many of the steps involved in preparation of therapeutic agents from fractionated plasma; thus, there is no presumed risk for transmission through these products.

h. A haemovigilance system should be in place to capture any possible cases of transmission through blood and components. Haemovigilance is invaluable in helping to understand the risk from blood and components and the overall effectiveness of the measures taken by the blood service.²

The decision as to whether to implement precautionary measures with their resulting impact on blood sufficiency and operational resources must be carefully considered. Measures introduced during one phase of the outbreak may also become impractical or unsustainable at another phase. For example, a country with no locally acquired cases may opt as a precaution to defer donors recently returned from affected areas. This is possible if the numbers of deferred potential donors are low and can easily be managed without affecting supply. However, once more countries are affected and particularly when locally acquired cases start to appear, the risk becomes more general and it is harder to identify individual at-risk donors. In such situations, deferral becomes impractical and unsustainable.

2. Mitigating the risk of staff and donor exposure to COVID-19 virus

Any transmission from a donor is far more likely to occur through the respiratory route than through parenteral routes (including phlebotomy during blood donation). It is possible that an infected donor who is asymptomatic, pre-symptomatic, or has very mild symptoms may infect other donors and staff. Strategies taken to mitigate this risk should be proportionate and evidence-based and should follow the public health measures taken in the country. Blood donor centres and manufacturing premises are not acute care medical facilities, and so public health measures appropriate to the general public rather than clinics and hospitals should be applied.

Donors and potential donors should be informed of the importance of self-deferral if they are feeling unwell, and of reporting immediately to the blood service any COVID-19 related illness within 28 days after donation. If COVID-19 is confirmed in a blood donor or staff, the management of contacts should follow national public health guidelines.

The safety of the donation process should be ensured through the use of appropriate protective measures by staff.⁹ Organisation of donation procedures to minimise contagion between donors, including physical distancing where feasible, may be considered while assuring proper flow of work.¹⁰ It is not necessary for precautions taken in health care settings with sick patients to be applied to donor centres unless the donor centre is sited within hospital premises or there is evidence of their effectiveness in community settings.

Standard laboratory biosafety practices, based on national or international guidelines, should be followed in all circumstances.¹¹ If blood service laboratories provide any pre-transfusion investigations, samples from patients suspected or confirmed with COVID-19 should be handled in accordance with COVID-19 guidance.¹²

Staff should be educated about COVID-19 and advised not to come to work if they feel ill or may have been exposed. Infection prevention and control measures should be reinforced.¹³ During widespread community transmission, staff may be reduced through illness; blood centres should consider measures to mitigate the impact on essential activities.

3. Mitigating the impact of reduced availability of blood donors

Reduction of donor numbers before, during and after a COVID-19 outbreak is a major risk for blood services. Blood services should consider the sufficiency risk early to enable preparedness and response. Blood donation numbers should be closely monitored so that measures can be taken quickly to pre-empt any decline in donor attendance or to consider importation of blood and components. This is particularly critical for components with short shelf life, such as platelets, where a constant supply is needed for patients dependent on platelet transfusions. A proactive communication strategy is needed to address donor anxiety, which often stems from lack of awareness, misinformation or fear of becoming infected during blood donation. Effective public awareness campaigns on the importance of maintaining an adequate national blood supply, need for blood donors, and safety of the donation process should be disseminated continuously.
Containment strategies may limit the ability of donors to attend donation sessions and prevent blood collection teams from visiting areas associated with infection clusters or where public health restrictions are in place. Strategies to overcome this may include rapid switching of sites for blood collections where feasible, providing donor transportation, intensifying efforts to schedule appointments for donations, or adjusting operating hours. Blood collection activities may need to be organized on a more targeted basis through recall of healthy repeat donors. Routine practices for donor management and infectious disease testing should not be changed. However, in the event of extreme blood shortages, reduction of whole blood donation intervals may be considered for donors with robust haemoglobin levels who are able to tolerate more frequent donations.

Systems should be in place to enable re-entry of infected donors after recovery. Most can donate again 28 days after full recovery. This may also support the collection of convalescent plasma for treatment of COVID-19 patients (see Section 7: Collection of convalescent plasma).

Importation of blood and components from unaffected areas of the country or another unaffected country (if permitted by regulatory authorities) is a potential solution if there are insufficient local stocks, although if widespread transmission is occurring, this may be difficult. There are also logistical issues with safely transporting blood and components.

4. Managing the demand for blood and blood products

Blood services should continually assess their blood stocks carefully in anticipation of uncertainty in the scale of collection activities. During widespread transmission, demand for blood and components may decrease as the health care system shifts toward treating increasing numbers of COVID-19 patients and elective surgeries and non-urgent clinical interventions are deferred. But blood transfusions will still be necessary for emergency situations such as trauma, post-partum haemorrhage, severe infant anaemia, blood dyscrasias, and urgent surgeries requiring availability of blood. Increased stocks may also be needed to support COVID-19 patients with severe sepsis or requiring extracorporeal membrane oxygenation support.

Good patient blood management will help safeguard blood stocks. The blood service must clearly communicate with health care professionals responsible for transfusion activities to ensure that blood and components are only used when clinically appropriate.

5. Ensure undisrupted supplies of critical material and equipment

Transport and trade restrictions, quarantine requirements, border control measures and production disruptions may decrease the global supply chain of critical materials and equipment used in blood and component collection, laboratory testing (including immunohaematology reagents and infectious disease screening assays). The blood service must take steps to ensure continuity of supplies.

6. Communication

Public and stakeholder confidence in the blood system is important. The blood service must communicate clearly to ensure that the national emergency response team, donors and recipients, and the public are properly informed and understand planned actions. Messaging and actions should be proportionate, evidence-based and consistent with overall national emergency response messaging.¹⁴,¹⁵

Within the blood service, all staff should understand the infectious threat and actions taken to ensure safety and reliability of the blood supply and the safety of staff and donors.

7. Collection of convalescent plasma

Experience suggests that empirical use of convalescent plasma (CP) may be a potentially useful treatment for COVID-19. Detailed risk assessment must always be conducted to ensure that the blood service has sufficient capability to safely collect, process and store these specific blood components in a quality-assured manner. WHO has previously released interim guidance for the use of CP collected from patients recovered from Ebola Virus Disease.¹⁶ Additionally, the WHO Blood Regulators Network Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus (2017) provides helpful considerations.¹⁷

References


Acknowledgements

This document was drafted by Dr Diana Teo, WHO Expert Advisory Panel member for blood transfusion medicine) in consultation with the Asia Pacific Blood Network and other international experts. As an informal WHO consultant Dr Jay Epstein of FDA contributed substantially in developing and finalizing the document incorporating inputs from experts within and outside WHO.

The following WHO staff contribute to or reviewed the current interim guidance:

Junping Yu, Yuyun Maryuningsih, François-xavier Lery (Technical Standards and Specification Unit, WHO HQ), André Loua (AFRO), Mauricio Beltrán Durán (AMRO), Yetmgeta E. Abdella (EMRO), Aparna Singh Shah (SEARO), Jinho Shin (WPRO).

The feedback given by the following experts, organizations and WHO teams is highly acknowledged:

Kamel Boukef, Nabajyoti Choudhury, Ana Emilia del Pozo, Peter Flanagan, Mahrukh Getshen, Alan Kitchen, Dora Mbanya, May Raouf, Ravi Reddy, Yongming Zhu, Shaminia Zou (Expert Advisory Panel members for blood transfusion medicine); Harvey Klein, Salwa Hindawi, Paul Strengers (ECBS Blood Tract members); Michael P. Busch, Louie M. Katz; Clive Seed (ISBT Technical Standards and Specification Unit, WHO HQ), Junping Yu, Yuyun Maryuningsih, François-xavier Lery (Technical Standards and Specification Unit, WHO HQ), Andrey Loua (AFRO), Mauricio Beltran Duran (AMRO), Yetmgeta E. Abdella (EMRO), Aparna Singh Shah (SEARO), Jinho Shin (WPRO).

The feedback given by the following experts, organizations and WHO teams is highly acknowledged:

Kamel Boukef, Nabajyoti Choudhury, Ana Emilia del Pozo, Peter Flanagan, Mahrukh Getshen, Alan Kitchen, Dora Mbanya, May Raouf, Ravi Reddy, Yongming Zhu, Shaminia Zou (Expert Advisory Panel members for blood transfusion medicine); Harvey Klein, Salwa Hindawi, Paul Strengers (ECBS Blood Tract members); Michael P. Busch, Louie M. Katz; Clive Seed (ISBT Technical Standards and Specification Unit, WHO HQ), Junping Yu, Yuyun Maryuningsih, François-xavier Lery (Technical Standards and Specification Unit, WHO HQ), Andrey Loua (AFRO), Mauricio Beltran Duran (AMRO), Yetmgeta E. Abdella (EMRO), Aparna Singh Shah (SEARO), Jinho Shin (WPRO).

The feedback given by the following experts, organizations and WHO teams is highly acknowledged:

Kamel Boukef, Nabajyoti Choudhury, Ana Emilia del Pozo, Peter Flanagan, Mahrukh Getshen, Alan Kitchen, Dora Mbanya, May Raouf, Ravi Reddy, Yongming Zhu, Shaminia Zou (Expert Advisory Panel members for blood transfusion medicine); Harvey Klein, Salwa Hindawi, Paul Strengers (ECBS Blood Tract members); Michael P. Busch, Louie M. Katz; Clive Seed (ISBT Technical Standards and Specification Unit, WHO HQ), Junping Yu, Yuyun Maryuningsih, François-xavier Lery (Technical Standards and Specification Unit, WHO HQ), Andrey Loua (AFRO), Mauricio Beltran Duran (AMRO), Yetmgeta E. Abdella (EMRO), Aparna Singh Shah (SEARO), Jinho Shin (WPRO).

The feedback given by the following experts, organizations and WHO teams is highly acknowledged:

Kamel Boukef, Nabajyoti Choudhury, Ana Emilia del Pozo, Peter Flanagan, Mahrukh Getshen, Alan Kitchen, Dora Mbanya, May Raouf, Ravi Reddy, Yongming Zhu, Shaminia Zou (Expert Advisory Panel members for blood transfusion medicine); Harvey Klein, Salwa Hindawi, Paul Strengers (ECBS Blood Tract members); Michael P. Busch, Louie M. Katz; Clive Seed (ISBT Technical Standards and Specification Unit, WHO HQ), Junping Yu, Yuyun Maryuningsih, François-xavier Lery (Technical Standards and Specification Unit, WHO HQ), Andrey Loua (AFRO), Mauricio Beltran Duran (AMRO), Yetmgeta E. Abdella (EMRO), Aparna Singh Shah (SEARO), Jinho Shin (WPRO).

The feedback given by the following experts, organizations and WHO teams is highly acknowledged:

Kamel Boukef, Nabajyoti Choudhury, Ana Emilia del Pozo, Peter Flanagan, Mahrukh Getshen, Alan Kitchen, Dora Mbanya, May Raouf, Ravi Reddy, Yongming Zhu, Shaminia Zou (Expert Advisory Panel members for blood transfusion medicine); Harvey Klein, Salwa Hindawi, Paul Strengers (ECBS Blood Tract members); Michael P. Busch, Louie M. Katz; Clive Seed (ISBT Technical Standards and Specification Unit, WHO HQ), Junping Yu, Yuyun Maryuningsih, François-xavier Lery (Technical Standards and Specification Unit, WHO HQ), Andrey Loua (AFRO), Mauricio Beltran Duran (AMRO), Yetmgeta E. Abdella (EMRO), Aparna Singh Shah (SEARO), Jinho Shin (WPRO).
Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19); interim guidance

WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change, WHO will issue a further update. Otherwise, this interim guidance document will expire 2 years after the date of publication.

© World Health Organization 2020. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.